These agents include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound), which also targets the glucose-dependent insulinotropic polypeptide (GIP) receptor
Tirzepatide, the only FDA-approved dual GIP/GLP-1 receptor agonist, is a peptide with potent and imbalanced co-agonism at both GIPR and GLP-1R
Develop a challenge to overcome and put a reward structure in placeyou can even get your partner or children involved as well
remains the primary theater for GLP-1 exclusivity battles, the global landscape is characterized by significant jurisdictional divergence
Depending on the cause, treatment may involve cardiology care or support from metabolic, neurology, nutrition, or nephrology teams